Full list of drugs that could be slashed under Trump's new executive order

President Donald Trump touted a new executive order that would more closely align drug prices in the US with those sold in Europe and the UK, opening the door for drugs used by millions of Americans to become cheaper.

The EO does not specify which drugs will be targeted but a similar policy proposed by Trump in 2020 included drugs administered in hospitals or clinics under Medicare Part B, which covers inpatient drugs for seniors. However, that policy was blocked by a federal judge who ruled the government had overstepped its bounds by sidestepping Congress.

That 2020 proposal narrowly covered Medicare Part B drugs, including immunosuppressants, chemotherapy, and vaccines for seniors. The new EO appears broader, referencing 'American patients' and 'public and private payers.'

US drug prices are three to five times higher than in other developed nations, with per-person spending double that of other wealthy countries - $963 in the US versus $466 on average elsewhere.

‘It's called Most Favored Nation,’ Trump said of the new policy. 'We're going to pay the lowest price there is in the world. We will get, whoever is paying the lowest price; that's the price that we're going to get.’

The Most Favored Nation policy long touted by President Donald Trump is designed to slash US drug prices by forcing pharmaceutical companies to offer Americans the same steep discounts they give other wealthy nations.

Before being implemented, the proposal would have to be approved by the members of Congress and Big Pharma is expected to lobby against the policy and sue to block it if it’s enacted.

Below, DailyMail.com compiled a list of the most costly prescription drugs under Medicare Part B that are expected to be included in Trump's Most Favored Nations plan.

Around one in eight Medicare enrollees use one of these drugs, and making prices align more with those in the EU would mean the government could afford to treat hundreds of thousands more people without increasing spending.

Cancer Treatments (Chemotherapy & Immunotherapy): TAKEN BY XX PEOPLE?

1. Keytruda (pembrolizumab)

- Cost per dose: $10,800–$15,200

- Used to treat melanoma, lung, bladder cancers, Hodgkin’s lymphoma

- What it could cost under the new EO: about $4,100 (Germany), a reduction of 73 percent

2. Opdivo (nivolumab)

- Cost per dose: $7,500–10,500

- Used to treat lung, kidney, liver, colorectal cancers

- What it could cost under the new EO: $2,800 (France), a reduction of 73 percent

3. Darzalex (daratumumab)

- Cost per dose: $6,500

- Used to treat multiple myeloma

- What it could cost under the new EO: $2,900 (Netherlands), a reduction of 55 percent

4. Rituxan (rituximab)

- Cost per dose: $5,200–8,000

- Used to treat non-Hodgkin’s lymphoma

- What it could cost under the new EO: $2,400 (Belgium), a reduction of 70 percent

5. Tecentriq (atezolizumab)

- Cost per dose: $8,200

- Used to treat bladder, lung, and breast cancers

- What it could cost under the new EO: $3,500 (Germany), a reduction of 57 percent

6. Herceptin (trastuzumab)

- Cost per dose: $4,500

- Used to treat anemia from chemotherapy

- What it could cost under the new EO: $1,900 (UK), a reduction of 58 percent

7. Procrit

- Cost per dose: $750

- Used to treat anemia

- What it could cost under the new EO: $320 (Spain), a reduction of 57 percent

Autoimmune & Inflammatory Diseases

1. Orencia (abatacept)

- Cost per dose: $1,600

- Used to treat rheumatoid arthritis

- What it could cost under the new EO: $700, a reduction of 54 percent

2. Actemra (tocilizumab)

- Cost per dose: $1,200

- Used to treat rheumatoid arthritis, Covd inflammation

- What it could cost under the new EO: $550, a reduction of 54 percent

3. Enbrel (etanercept)

- Cost per dose $1,600

- Used to treat psoriasis, psoriatic arthritis

- EU average cost per dose: $700 (Spain)

- What it could cost under the new EO: $700, a reduction of 56 percent

4. Stelara (ustekinumab)

- Cost per dose: $14,000

- Used to treat psoriasis, Crohn’s disease

- What it could cost under the new EO: $6,500, a reduction of 54 percent

5. Xolair (omalizumab)

- Cost per dose: $1,300

- Used to treat severe asthma, chronic hives

- What it could cost under the new EO: $600, a reduction of 117 percent

Neurological & Rare Diseases

1. Tysabri (natalizumab)

- Cost per dose: $7,000

- Used to treat multiple sclerosis, Crohn’s

- What it could cost under the new EO: $3,200 a reduction of 119 percent

2. Soliris (eculizumab)

- Cost per dose: $32,000

- Used to treat PNH, aHUS (rare blood disorders)

- What it could cost under the new EO: $18,000 a reduction of 78 percent

Eye Diseases

1. Eylea (aflibercept)

- Cost per dose: $1,850

- Used to treat wet AMD, diabetic retinopathy

- What it could cost under the new EO: $800 a reduction of 131 percent

2. Lucentis (ranibizumab)

- Cost per dose: $1,200

- Used to treat wet AMD, macular edema

- What it could cost under the new EO: $450 a reduction of 167 percent

Supportive Care (Chemo Side Effects/Bone Health)

1. Neulasta (pegfilgrastim)

- Cost per dose: $6,200

- Boosts white blood cells post-chemo

- What it could cost under the new EO: $2,800, a reduction of 121 percent

2. Prolia (denosumab)

- Cost per dose: $1,300 O

- Used to treat osteoporosis (cancer-related bone loss)

- What it could cost under the new EO: $600, a reduction of 117 percent

Other High-Cost Therapies

1. Rebif (interferon beta-1a)

- Cost per dose: $3,600/month

- Used to treat multiple sclerosis

- What it could cost under the new EO: $1,500, a reduction of 140 percent

2. Nucala (mepolizumab)

- Cost per dose: $4,000

- Used to treat severe asthma

- What it could cost under the new EO: $1,800, a reduction of 122 percent

Trump told reporters on Monday that a major facet of his plan is to force other countries to pay more to pharmaceutical companies or risk losing access to the US market

Read More

He said: ‘You have to also charge other nations more.' Because they’re really — we’re bearing the cost of all of this.

‘We have people – rich countries – paying a tiny fraction of what we pay.

'We’re talking about 10 percent, 20 percent, 30 percent of what we pay. We can’t do that, and we’re not going to do it anymore.

Trump also vowed to 'get rid of the middlemen,' targeting pharmacy benefit managers (PBMs).

PhRMA also blames PBMs, which negotiate drug coverage for insurers like Aetna and collect manufacturer rebates—often keeping more than half the spending.

Ubl, CEO of PhRMA, said: ‘The US is the only country in the world that lets PBMs, insurers and hospitals take 50 percent of every dollar spent on medicines.

'The amount going to middlemen often exceeds the price in Europe.’

Trump, meanwhile, said: ‘We’re doing things nobody ever thought could be done. The middlemen became very, very rich.’

In Europe, government-run health systems negotiate drug prices directly with pharmaceutical companies, bypassing middlemen.

Countries like the UK, France, and Germany have national agencies that determine coverage and set prices nationwide—eliminating the need for pharmacy benefit managers (PBMs) common in the U.S.

This direct negotiation avoids inflated prices, rebate schemes, and pharmacy markup practices.

Trump said: ‘Starting today, the United States will no longer subsidize the health care of foreign countries, which is what we were doing… where they paid a small fraction for the same drug than what many, many times more for.

‘And we no longer tolerate profiteering and price-gauging from big pharma. It was really the countries that forced big pharma to do things that, frankly, I'm not sure they really felt comfortable doing.

‘But they've gotten away with it, these countries.’